Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

Phase 2 Terminated 47 enrolled Jazz Pharmaceuticals Jazz Pharmaceuticals Ireland Limited · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.

Timeline

Start: 2022-03-03
Primary completion: 2023-12-20
Completion: 2023-12-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lurbinectedin	Other / unclassified	3.2 mg/m2	Intravenous

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

Summary

Timeline

Drugs

Indications